Fierce Pharma
OCTOBER 14, 2024
Four days after a compounding industry group filed a lawsuit against the FDA | Four days after a compounding industry group filed a lawsuit against the FDA for removing Eli Lilly’s tirzepatide products from its shortage list, the U.S. regulator is taking a second look at its decision.
pharmaphorum
OCTOBER 14, 2024
Eli Lilly may invest $364m in the UK and work with the government to tackle serious public health challenges including obesity.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
OCTOBER 14, 2024
On a mission to collect a key Crohn’s disease approval and build out its inflammatory bowel disease (IBD) profile, Eli Lilly has notched a trial win over a major rival in a head-to-head study.  | Eli Lilly's drug outperformed Johnson & Johnson's established Stelara in a phase 3 study that looked at histologic disease responses over 52 weeks.
MedCity News
OCTOBER 14, 2024
Suki’s $70 million Series D financing round was led by Hedosophia and included participation from Venrock, March Capital, Flare Capital, Breyer Capital and inHealth Ventures. The post Suki Secures $70M To Expand AI Offerings appeared first on MedCity News.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
OCTOBER 14, 2024
Awaiting a potential acquisition by Novo Holdings, Catalent is giving its contract manufacturing compatriot a boost as Ardena plots its U.S. debut. | Catalent is selling its oral solids facility in Somerset, New Jersey, to Belgium’s Ardena for an undisclosed sum. The site also doubles as Catalent's current corporate headquarters.
MedCity News
OCTOBER 14, 2024
Lundbeck says Longboard Pharmaceuticals’ drug, bexicaserin, has potential applications in a range of rare epilepsies. Last month, the biotech began a Phase 3 clinical trial testing the drug in Dravet syndrome. The post Lundbeck’s Neuro-Rare Pipeline Lands Cornerstone Drug via $2.6B Longboard Pharma Acquisition appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
OCTOBER 14, 2024
We need to equip pharmacists with technology that can help them to make impactful clinical interventions in the pharmacy and reimburse them for these services, which would help to address the provider shortage. The post Community Pharmacies Fill Critical Healthcare Gaps in Rural Areas — Here’s How We Can Empower and Support Them appeared first on MedCity News.
Fierce Pharma
OCTOBER 14, 2024
By Lalit Saxena, Senior Director of MSAT, and Sungkeum Seo, Director of MSAT Labs Upstream Processing at Samsung BiologicsIntroduction | The biopharmaceutical industry is expanding rapidly, driven by an increasing demand for complex biomedicines. Today, manufacturing biomolecules presents unique challenges, like cost pressure and market uncertainty.
MedCity News
OCTOBER 14, 2024
By moving beyond subjective and heterogeneous criteria and embracing objective brain function measures, the field of psychiatry can achieve greater precision and efficacy in addressing complex disorders. The post Precision Psychiatry is Possible — Especially if We Use Evidence-based Neural Measures to Drive Better Mental Health Treatment and Outcomes appeared first on MedCity News.
Fierce Pharma
OCTOBER 14, 2024
As payers tally up the potential costs of anti-amyloid antibodies for Alzheimer’s disease, a new study suggests that the vial design for Eisai and Biogen’s Leqembi could result in hundreds of milli | As payers tally up the potential costs of anti-amyloid antibodies for Alzheimer’s disease, a new study suggests that the vial design for Eisai and Biogen’s Leqembi could result in hundreds of millions of dollars in wasted spending each year for Medicare.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
OCTOBER 14, 2024
Trends in gene therapy approvals in recent years are rapidly shaping the future of manufacturing capabilities in the pharmaceutical industry.
pharmaphorum
OCTOBER 14, 2024
Damage to a Baxter manufacturing facility caused by Hurricane Helene, which rolled across the east US a couple of weeks ago, has led to shortages in some critical medicines.The plant in North Cove, North Carolina, was severely affected by flooding and had to be shut down at the end of September. It is Baxter's biggest manufacturing site and is also the largest supplier of intravenous and peritoneal dialysis solutions to the US market.
Pharmaceutical Technology
OCTOBER 14, 2024
RHEACELL has been researching ABCB5-positive stem cell therapies for patients with severe immune and inflammation-related diseases for which there are currently no adequate treatment options. Positive feedback from the regulatory authorities on the study program now gives reason to hope that those affected will be able to benefit from this new approach to regenerative medicine in the near future.
pharmaphorum
OCTOBER 14, 2024
For the first time, a vaccine candidate for Rift Valley fever, developed by Oxford University, has been advanced into a phase 2 trial backed by CEPI.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Pharmaceutical Technology
OCTOBER 14, 2024
Sanofi has announced negotiations with Clayton Dubilier & Rice (CD&R), regarding the potential sale of a 50% controlling stake in Opella.
pharmaphorum
OCTOBER 14, 2024
GSK's six-monthly IL-5 inhibitor depemokimab clears two phase 3 trials in chronic rhinosinusitis with nasal polyps (CRSwNP), its second indication
European Pharmaceutical Review
OCTOBER 14, 2024
The first anti-tissue factor pathway inhibitor (anti-TFPI) treatment for haemophilia A or B in the US has been approved by the US Food and Drug Administration (FDA). Hympavzi (marstacimab-hncq) is authorised for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in individuals 12 years of age and over with haemophilia A or haemophilia B without inhibitors.
pharmaphorum
OCTOBER 14, 2024
Faced with lawsuit, FDA rethinks block on compounding pharmacies making Eli Lilly's diabetes and obesity drug tirzepatide
PharmaVoice
OCTOBER 14, 2024
Long-time executives with a strong track record of advancing drug R&D, business savvy strategies and leadership in various sectors of pharma.
Pharmaceutical Commerce
OCTOBER 14, 2024
The company’s annual edition reveals the latest numbers in the sector, including a rise in average employer-sponsored health insurance premiums for single and family coverage of 24% and 28% respectively.
PharmaVoice
OCTOBER 14, 2024
Digital therapeutics have languished in the background of traditional medicines for years, but a recent reimbursement push may have gotten the ball rolling.
PharmaTimes
OCTOBER 14, 2024
Phase 2 study of TG4001 shows promise in cervical cancer patients
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Pharma Marketing Network
OCTOBER 14, 2024
In the ever-evolving landscape of pharmaceutical marketing, the traditional methods of reaching healthcare professionals and consumers are gradually being supplemented by innovative digital strategies. Among these, influencer marketing has emerged as a powerful tool for pharma companies seeking to build trust and foster engagement with their target audiences.
PharmExec
OCTOBER 14, 2024
The Big Pharma commercialization playbook doesn’t work for emerging life sciences companies bootstrapping their way up. Exploring three strategies that could be the ingredients of a winning formula for startups.
Pharma Marketing Network
OCTOBER 14, 2024
The pharmaceutical industry is undergoing unprecedented changes driven by technological advancements, regulatory shifts, and a more informed patient base. As the landscape evolves, pharma executives must adapt their marketing strategies to remain competitive and effectively reach their target audiences. This article explores the key trends reshaping the industry and offers insights into innovative marketing approaches and strategies that pharma executives can employ to navigate these changes suc
PharmExec
OCTOBER 14, 2024
Rafaat Rahmani, president and founder of Lifescience Dynamics, grew up in abject poverty, but such hardships—and a later violent brush with racism—would ultimately end up fueling a determined and entrepreneurial path in the life sciences.
PharmaTech
OCTOBER 14, 2024
Ahmed Youssef, senior manager, USP Process Development at Ascend, provides insight on tech transfer when developing and manufacturing emerging therapies and new modalities.
PharmExec
OCTOBER 14, 2024
Hympavzi is the first anti-tissue factor pathway inhibitor therapy to be approved in the United States for routine prophylaxis of bleeding in patients with hemophilia A or B without inhibitors.
PharmaTimes
OCTOBER 14, 2024
Acquisition to enhance Lundbeck’s neuroscience pipeline
PharmExec
OCTOBER 14, 2024
Acquisition of Longboard grants Lundbeck access to bexicaserin, 5-HT2C receptor agonist that has demonstrated promise in treating seizures associated with rare developmental epileptic encephalopathies.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
288 
Let's personalize your content